Cell And Gene Therapy Manufacturing

  1. Pipeline Progress 8/18/2023

    Experts working on robust pipelines that focus on various therapeutic areas explain how process automation looks different per therapeutic focus area.

  2. Scaling Viral Vectors 11/13/2023

    Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.

  3. mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A 1/29/2024

    During our Cell & Gene Live, mRNA For Cancer Immunotherapy 2024 Outlook, our expert panelists answered audience questions regarding patient safety, foreseeable challenges in mRNA cancer immunotherapy for solid tumors, and much more.

  4. Major Trends Impacting Allogeneic Cell Therapies For Oncology 5/6/2024

    We kicked off this Cell & Gene Live, Unlocking the Future of Allogeneic Cell Therapy for Oncology by discussing the major trends impacting allogeneic cell therapies for oncology.

  5. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  6. Unlocking The Future Of Allogeneic Cell Therapy For Oncology | Audience Q&A 5/6/2024

    Expert panelists in this Cell & Gene Therapy Live presentation provided detailed responses to questions about the potential risks of CAR-T therapy, screening criteria for donor material, comparability, and more.

  7. Planning for Success: Supply Resiliency Strategies for Bench to Production 10/18/2023

    Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.

  8. Improvements In Scaling And Sequencing For Allogeneic Cell Therapies For Oncology 5/6/2024

    During this segment, Nguyen and Wagner agree that scalability will be a top concern for most CGT companies.

  9. Thermo Fisher Scientific Large Volume Liquid Expansion 5/2/2024

    This video provides an insightful look into the expansion of the large volume liquids manufacturing site at the Grand Island facility, highlighting the various stages of the manufacturing process and the capabilities it offers to support the bioprocessing industry.

  10. The Need for Speed: Dr. Peter Marks and Dr. Nicole Verdun Explain Meeting Unmet Need for Pediatric Patients 1/30/2024

    How can sponsor companies accelerate development in pediatric patients for genetic diseases that affect both children and adults, but where gene therapy holds the greatest promise to address unmet needs in pediatric patients?